BSBrent A. Senior

Brent A. Senior

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Brent A. Senior has a total of 407 co-authors. Here are the top co-authors by number of shared publications:

  • Brian D. Thorp

    Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA

    23 shared publications
  • Charles S. Ebert

    Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA

    23 shared publications
  • Adam J. Kimple

    Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA

    17 shared publications
  • Adam J. Kimple

    Department of Otolaryngology–Head and Neck Surgery University of North Carolina at Chapel Hill Chapel Hill North Carolina USA

    12 shared publications
  • Cristine Klatt‐Cromwell

    Department of Otolaryngology—Head and Neck Surgery University of North Carolina School of Medicine Chapel Hill North Carolina USA

    10 shared publications
  • Ezer H. Benaim

    Department of Otolaryngology—Head & Neck Surgery University of North Carolina Chapel Hill North Carolina USA

    7 shared publications

Latest Publications

  • Open Access

    A Single‐Cell Atlas of Juvenile Nasopharyngeal Angiofibroma Identifies Endothelial Remodeling and Candidate VEGF‐Pathway Targets

    by Heidi Martini‐Stoica, Brittany T. Rupp, Meik Kunz, Alessandra Livraghi‐Butrico, Kenichi Okuda, Wanda K. O'NEal, Scott H. Randell, Hong Dang, Hiroaki Murano, Minako Furusho, et al.

    Background: Juvenile nasopharyngeal angiofibroma (JNA) is a rare locally aggressive vascular sinonasal tumor that primarily affects adolescent males. Despite advances in endoscopic surgery and preoperative embolization, JNA can be associated with major operative bleeding risk and clinically meaningful recurrence, while non‐surgical treatment options remain limited. Methods: To define the cellular programs underlying JNA vascularity, we performed single‐cell RNA sequencing of post‐embolization JNA tumors ( n =  2), tumor‐adjacent mucosa, and control sinonasal tissue. We analyzed cell composition, differential gene expression, pathway enrichment, and cell–cell communication, followed by Drug2cell‐based mapping of transcriptional states to candidate therapeutic targets. Results: JNA contained an expanded fibrovascular compartment composed of endothelial cells, fibroblasts, pericytes, vascular smooth muscle cells, and neuronal‐like cells. Neuronal‐like cells were enriched in JNA but showed relatively limited transcriptional differences from tumor‐adjacent tissue. By contrast, endothelial cells demonstrated the strongest disease‐associated remodeling, with enrichment of angiogenesis, extracellular matrix organization, hypoxia response, and cell migration pathways. Endothelial cells also showed downregulation of adaptive immune signaling pathways, suggesting reduced immune engagement within the tumor microenvironment. Intercellular communication analyses revealed dense endothelial‐stromal signaling across the JNA fibrovascular network. Drug2cell analysis nominated VEGF/VEGFR signaling as a candidate drug target, with VEGFR‐inhibiting agents predicted to act primarily on endothelial populations. Conclusions: JNA is organized around an angiogenesis‐dominant fibrovascular program driven by endothelial‐centered signaling. These data support further investigation of VEGF/VEGFR‐directed inhibition as a potential adjunctive strategy for patients with recurrent, unresectable, or surgically high‐risk JNA.

  • Open Access

    A Pilot Study on the Relationship Between Time to Formalin Fixation and Changes in Eosinophil Infiltration in Nasal Polyps

    by Priya J. Desai, Kosuke Tochigi, Nathan R. Barefoot, Elena Quinonez Del Cid, Katrina Bootes, Cristine Klatt-Cromwell, Charles S. Ebert, Brian Thorp, Kazuhiro Omura, Yasuhiro Tanaka, et al.

    Background: Tissue eosinophil counts are commonly used as prognostic markers in chronic rhinosinusitis with nasal polyps (CRSwNP) and to determine eligibility for financial assistance based on established criteria, highlighting an evolving importance. However, no standardized protocols govern specimen handling from collection to formalin fixation yet. This gap in practice is clinically meaningful, as the effect of pre-fixation delay on eosinophil counts and epithelial integrity remains poorly defined. Objective: To determine whether time to formalin fixation influences eosinophil counts and epithelial integrity in nasal polyps from patients with CRSwNP. Methods: Clinical nasal polyp specimens processed through our institution's standard surgical pathology workflow and a controlled research protocol were evaluated histologically with hematoxylin and eosin staining. For clinical specimens, time from collection to fixation was recorded and eosinophils were enumerated. In the experimental portion, research specimens were sectioned and fixed at 0 h, 1 day, 3 days, and 7 days after excision. Eosinophil counts and epithelial injury scores were compared across time intervals and correlated with fixation delay. Results: Time to formalin fixation ranged from 51 min to 19 h, and longer delays correlated with greater eosinophil reduction ( r = −0.867, p = .057). In the experimental portion, eosinophil counts were lower at 1, 3, and 7 days than at 0 h ( p < .05), and fixation time was negatively correlated with eosinophil count ( r = −0.39, p < .05). Epithelial injury scores increased at 1, 3, and 7 days ( p < .05), and positively correlated with fixation time ( r = 0.72, p < .05). Conclusions: Delayed formalin fixation reduces eosinophil counts and worsens epithelial preservation in nasal polyps. Standardization of tissue handling and fixation timing may improve the reliability of histologic eosinophil assessment in CRSwNP patients.

  • Timing of Rituximab Initiation and Rhinologic Outcomes in Granulomatosis With Polyangiitis

    by Ismail M. Khaderi, Nathan R. Barefoot, James M. Hardy, Nithya P. Gurumurthy, Jack Womble, Sean A. Celli, David J. Dillard, Kosuke Tochigi, Priya J. Desai, Elena Quinonez Del Cid, et al.

  • Predictors of Refractory Primary Chronic Rhinosinusitis Following Endoscopic Sinus Surgery

    by Ismail M. Khaderi, Kosuke Tochigi, Nathan R. Barefoot, Priya J. Desai, Elena Quinonez Del Cid, Katrina Bootes, Kazuhiro Omura, Yasuhiro Tanaka, Cristine Klatt‐Cromwell, Jackson R. Vuncannon, et al.

    Background: Refractory chronic rhinosinusitis (CRS) after functional endoscopic sinus surgery (FESS) has traditionally been defined by revision surgery alone. With the emergence of biologic therapies, treatment escalation now includes revision surgery and/or biologic initiation. We sought to identify independent predictors of refractory primary CRS using a composite outcome incorporating surgery and/or biologic initiation. Methods: Adult patients with primary CRS undergoing FESS after 2015 were identified in the TriNetX Research Network. Patients with secondary CRS, prior biologic therapy, or sinonasal neoplasms were excluded. The primary outcome was refractory CRS, defined as revision FESS or biologic initiation from 3 months to 5 years postoperatively. Preoperative covariates were evaluated using Cox proportional hazards modeling with stepwise selection. Results: Among 24,759 patients, 2866 (11.6%) had refractory CRS after FESS. Of these, 66.6% underwent revision FESS, 42.0% initiated biologic therapy, and 8.7% had revision surgery and initiated a biologic therapy. In multivariable analysis, asthma was the strongest predictor (HR 2.06, p < 0.001), followed by allergy to analgesic agents (e.g., NSAIDs) (HR 1.87, p < 0.001), nasal polyps (HR 1.67, p < 0.001), food allergy (HR 1.37, p = 0.096), COPD (HR 1.27, p = 0.006), eosinophilia (HR 1.27, p < 0.001), and Black or African American race (HR 1.16, p = 0.044). Conclusion: Refractory CRS following FESS is strongly associated with type 2 inflammatory comorbidities and select demographic factors. Incorporating biologic therapy into outcome definitions provides a contemporary framework for risk stratification and postoperative counseling.

  • Open Access

    Biologics Adoption in CRSwNP and the Associated Decline in Endoscopic Sinus Surgery: A Longitudinal Claims Database Study

    by Stephanie Shintani Smith, Sam L. Kaefer, Harsh Duvvuru, Robert C. Kern, Brent A. Senior, Vijay R. Ramakrishnan

    Background: Biologic treatments were introduced for chronic rhinosinusitis with nasal polyps (CRSwNP) in 2019. Treatment algorithms for medically refractory CRSwNP remain open, with patients choosing among surgery, biologics, or both. Real‐world utilization of surgery and biologics remains incompletely characterized. Objective: The aim of the study is to evaluate temporal trends in endoscopic sinus surgery (ESS) and biologic utilization in relation to 2019 Food and Drug Administration approval of biologics for CRSwNP. Methods: Retrospective study of CRSwNP ESS and biologic prescription rates, patient demographics, and comorbidities within the Merative MarketScan Research database (2016–2024). Quarterly and annual trends were evaluated by regression and interrupted time series analyses. Results: A total of 59,953 CRSwNP patients were included. Annual ESS rates declined, whereas biologic prescriptions increased markedly from 2016 to 2024. Dupilumab dominated among biologic alternatives. Interrupted time series analysis demonstrated a sharp decline in ESS rates with the 2019 introduction of biologics for CRSwNP, whereas biologic use grew continuously across 2016–2024 with a large increase in 2019–2020. Combination ESS and biologic treatment is growing but remains relatively infrequent. Patients receiving biologics were older and suffered from type 2 inflammatory comorbidities, such as asthma and allergic rhinitis ( p <0.001 for both). Conclusion: In CRSwNP, biologic treatment has increased significantly in recent years, particularly in older patients or those with type 2 inflammatory comorbidities. Overall ESS utilization in CRSwNP has declined, and combination ESS and biologics are an emerging phenomenon. These figures reveal the extent of evolution in CRSwNP treatment induced by targeted medical therapies in real‐world practice and serve as a foundation for healthcare utilization discussions.

  • Bevacizumab Reduces Epistaxis‐Related Operative Burden in Hereditary Hemorrhagic Telangiectasia

    by Nathan Barefoot, Priya J. Desai, Anna van Dorsten, Elena Quinonez Del Cid, Katrina Bootes, Ismail Khaderi, Ezer H. Benaim, Jackson Vuncannon, Cristine Klatt‐Cromwell, Charles S. Ebert, et al.

    Key Points: Bevacizumab reduced epistaxis‐related ablation frequency by 55.6% in HHT patients. Over half of HHT patients (57.7%) required no ablation intervention after bevacizumab initiation. Maintenance bevacizumab dosing remains highly variable, underscoring the need for standardization.

  • Effects of Sinonasal Mucus Debridement on Nasal Nitric Oxide in Primary Ciliary Dyskinesia

    by Nathan R. Barefoot, John B. Henrich, Elena Quinonez Del Cid, Priya J. Desai, Katrina Bootes, Jackson Vuncannon, Cristine Klatt‐Cromwell, Brian D. Thorp, Charles S. Ebert, Brent A. Senior, et al.

  • Open Access

    Determining the Minimal Clinically Important Difference of the 40‐Item Smell Identification Test in People With Cystic Fibrosis

    by Eugene Oh, Jessa E. Miller, Michelle J. Lee, Anna Zemke, David Baraghoshi, Matthew J. Strand, Jeremiah A. Alt, Todd E. Bodner, Michael Chang, Naweed I. Chowdhury, et al.

    Background: Chronic rhinosinusitis (CRS) and olfactory dysfunction (OD) are highly prevalent among people with cystic fibrosis (PwCF) and negatively impact quality of life. The 40‐item Smell Identification Test (SIT) is widely used to assess psychophysical olfaction, but a CF‐specific minimal clinically important difference (MCID) has not been established. This study aimed to determine the SIT MCID in PwCF treated with elexacaftor/tezacaftor/ivacaftor (ETI) and/or endoscopic sinus surgery (ESS). Methods: Data from three prospective, multi‐institutional observational studies were pooled. Participants were ≥12 years old with confirmed CF and CRS who completed SIT at baseline and ≥1 follow‐up (3, 6, 9, 12, or 24 months). Distribution‐based MCIDs were calculated using four methods: standard error of measurement (SEM), minimal detectable change (MDC = 1.96 × SEM), 0.5 × baseline standard deviation (SD), and 0.5 × SD of change scores (ΔSD). Results: A total of 122 participants were enrolled (mean age 32.9 years, 54% female). Of these, 99 contributed follow‐up SIT scores (79 ETI, 20 ESS). SIT scores remained stable with ETI, with a small but statistically significant decline at 6 months (−1.4, p = 0.02). ESS was associated with mean gains of 3.1–4.5 points at early follow‐up, though these did not reach significance. Pooled distribution‐based MCID estimates ranged from 2 to 4 points, with an overall threshold of 3.1 (95% CI: 2.1–4.1). Conclusions: This CF‐specific SIT threshold provides a clinically interpretable cut‐off for assessing olfaction. These findings establish a foundation for future work and highlight the importance of developing disease‐specific MCIDs to guide clinical care and research.

  • Assessment of Lifetime Inhalational Exposure Burden and Associations With Chronic Rhinosinusitis

    by Nina M. Westcott, Michael Ly, Anna Van Dorsten, Cameron P. Worden, Ezer H. Benaim, Charles Ebert, Jackson R. Vuncannon, Brian D. Thorp, Cristine N. Klatt‐Cromwell, Christine E. DeMason, et al.

    Key Points: Environmental and occupational inhalational exposures are linked to chronic rhinosinusitis The Sinonasal Occupational Airborne Pollutant Exposure (SOAPE) survey assesses lifetime exposure to inhalational irritants CRS patients who underwent sinus surgery reported higher inhalational exposures


  • Open Access

    Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis

    by Christine M. Liu, Jakob L. Fischer, Jonathan B. Overdevest, Anna C. Zemke, Matthew J. Strand, David A. Gudis, Adam J. Kimple, Jeremy P. Tervo, Emily DiMango, Jennifer L. Goralski, et al.